Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
Proteomics for precision medicine: Next-generation testing to
indicate future cardiovascular risk and improve outcomes
Proteomic testing can reveal multiple answers to clinical questions that allow providers to better predict, monitor, and prevent the escalation of cardiovascular disease (CVD). This allows providers to move the needle away from the practice of late-stage treatment and toward treating at-risk patients sooner and before a major cardiovascular (CV) event.
Topics covered include:
- The capabilities of proteomics
- How comprehensive protein detection technology can accurately predict major cardiovascular events
- How proteomic testing can ultimately improve outcomes
Nelson Trujillo, MD
Cardiologist
Boulder Heart at Anderson Medical Center
Rosalyn Gill, PhD
Vice President, Medical Affairs
SomaLogic, Inc.
Todd Johnson
Executive Vice President, Diagnostics
Business Unit
SomaLogic, Inc.
Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes
A presentation by Nelson Trujillo, MD, Rosalyn Gill, PhD, and Todd Johnson
More webinars
WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
WebinarProteomics for precision neuroscience: the power of protein analysis
This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.
WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.